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Abstract 
Background: Chronic pancreatitis (CP) patients frequently experience malabsorption 
and maldigestion, leading to micro- and macronutrient deficiencies. Co-morbid diabetes 
and lifestyle habits, such as alcohol consumption, may impact nutritional status.  
 
 
Methods: We compared micronutrient antioxidant, bone metabolism, serum protein, 
and inflammatory marker levels in 301 CP patients and 266 controls with no known 
pancreatic disease. We analyzed serum prealbumin and retinol binding protein, 
vitamins A, D, E, and B12, osteocalcin, tumor necrosis factor- α and C-reactive protein 
(CRP). We also evaluated biomarkers among subsets of patients, examining factors 
including time since diagnosis, body mass index, alcohol as primary etiology, diabetes 
mellitus, vitamin supplementation, and pancreatic enzyme replacement.   
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Results: After correcting for multiple comparisons, CP patients had significantly lower 
levels of vitamin A (40.9 vs. 45.4 µg/dL) and vitamin E (both α- [8.7 vs. 10.3 mg/L] and 
γ- [1.8 vs. 2.2 mg/L] tocopherol), as well as osteocalcin (7.9 vs. 10 ng/ml) and 
prealbumin 23 vs. 27 mg/dL), than controls. Both patients and controls that took 
vitamin supplements had higher serum levels of vitamins than those not taking 
supplements. Compared with controls, in controlled analyses, CP patients had 
significantly lower levels of vitamins A, D, and E (both α- and ϒ-tocopherol). CP patients 
also had significantly lower levels of osteocalcin, prealbumin and retinol binding 
protein, and higher CRP. 
 
 
Conclusions: CP patients demonstrated lower levels of selected nutritional and bone 
metabolism biomarkers than controls. Diabetes and alcohol did not impact biomarkers. 
Vitamin supplements and pancreatic enzyme replacement therapy improved nutritional 
biomarkers in CP patients. 
 
 
Introduction 
The exocrine pancreas produces pancreatic enzymes to hydrolyze complex nutrients 
for further digestion and absorption by the intestinal mucosa while the endocrine pancreas 
secretes the hormones necessary for nutrient utilization.  Chronic pancreatitis (CP) is a 
pathologic fibro-inflammatory syndrome of the pancreas in individuals with genetic, 
environmental, or other risk factors who develop persistent pathologic responses to 
parenchymal injury or stress.1 CP causes progressive replacement of functional exocrine and 
endocrine tissue with fibrosis and manifests clinically by maldigestion, steatorrhea, weight 
loss, abdominal pain and diabetes mellitus.2, 3 CP may cause severe malnutrition and 
metabolic derangements if proper treatment is not provided.4-8 
Mechanistically, CP affects nutrition through at least four mechanisms.  First, oral 
intake may be diminished because of sitophobia (fear of eating due to pain), or selective 
avoidance of nutrients such as fat due to steatorrhea, bloating, or diarrhea.  Secondly, 
reduced pancreatic digestive enzyme secretion impairs the digestion of triglycerides, 
causing reduced absorption of fat and fat-soluble vitamins A, D, E, and K, while diminished 
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proteases may cause protein malnutrition and vitamin B12 deficiency.  Thirdly, chronic 
inflammation may produce an anabolic state that impairs protein utilization.  Finally, the 
loss of islet of Langerhans cells results in metabolic disturbances due to diminished insulin, 
glucagon, and pancreatic polypeptide secretion. Individual CP patients may manifest any 
combination and degree of these mechanisms. 
We previously reported significantly lower body mass index (BMI, kg/m2) in patients 
with CP than those with recurrent episodes of acute pancreatitis or controls.9 Low BMI 
correlates with severity indicators of CP and poor quality of life.10 Change in BMI after the 
onset of CP may be an even more accurate measure of the effects of CP on nutrition. Active 
inflammation, regardless of pancreatic secretory function, can affect nutrition by decreasing 
appetite and driving catabolism.  Indeed, inflammation and malnutrition have been shown 
to correlate, particularly when protein is deficient.11-13 Levels of serum proteins, such as 
albumin, prealbumin and retinol-binding protein (RBP), are often lower in CP patients than 
in healthy individuals, and have frequently been used as a sign of protein-calorie 
malnutrition.14, 15 However, levels of negative acute phase reactants such as albumin and 
prealbumin can be diminished when an individual has physiologic stress, such as during an 
infection, or in people with liver disease.16 Combined consensus statements from Academy 
of Nutrition and Dietetics the American Society for Parenteral and Enteral Nutrition 
(A.S.P.E.N.) as well as 2016 guidelines for nutritional support from the Society of Critical 
Care Medicine/A.S.P.E.N. have noted that prealbumin levels are inversely related to 
inflammatory cytokines.17, 18Although unreliable, physicians still often rely on these 
biomarkers as a clinical reflection of protein status. Malabsorption of nutrients and 
micronutrients and may contribute to elevated inflammatory cytokines and markers of 
oxidative stress.19, 20 Thus, CP patients may enter a vicious cycle of antioxidant 
micronutrient deficiencies and inflammation-associated damage, where increased oxidative 
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stress occurs simultaneously with decreased antioxidant protection, especially in 
diabetics.19-22 Micronutrient deficiencies also predispose to oxidative stress in other 
systems, increasing the risk of illnesses such as cancer.23-25 
 Fat metabolism may be abrogated in CP. Lipase and apolipoprotein C-II deficiencies 
are two inborn errors of metabolism associated with CP.26-28 Lipase deficiency also causes 
fat malabsorption, affecting fat-soluble vitamin status.29 Low levels of serum lipids, fatty 
acids, and vitamins A and E often occur in CP patients.21, 30-33 Vitamin D is essential to bone 
health and bone metabolism. Vitamin D depletion has been noted in men and women of all 
ages with CP.29, 30, 34   A study of 73 patients (17 women and 56 men) in different stages of CP 
noted the presence of osteopathy in 39% of patients, observing osteopenia in 26%, 
osteoporosis in 5%, and osteomalacia in 8% of cases.30 A 2014 meta-analysis that included 
10 studies for a total of 513 CP patients, noted that patients had a pooled prevalence rate of 
osteoporosis of 23.4% (95% confidence interval, 16.6-32.0).35 CP is associated with lower 
circulating levels of vitamin D3 and decreased bone mineral density, loss of skeletal mass, 
and an increased risk of diabetes mellitus.36-38  
Pancreatic enzyme replacement therapy (PERT) is currently the most effective means 
of treating maldigestion and malabsorption in CP patients.39, 40 Although guidance for 
treating pancreatic enzyme insufficiency in cystic fibrosis is established, variable etiology, 
diet, lifestyle factors, comorbidities and metabolic demands in adults with CP makes 
standardizing PERT guidance challenging.  Controlled studies demonstrate that, with or 
without gastric acid suppression, some CP patients may require higher doses of PERT to 
achieve adequate absorption of dietary nutrients.41        
To date, there have been a limited number of published investigations of malnutrition 
and vitamin deficiencies in CP.33, 42 While many studies evaluating nutrition in pancreatitis 
have been of fairly high quality, most have been small in size, with fewer than 100 patients 
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included in the analyses.15, 43-48 Some have not included any female patients.42, 48-50 We 
utilized the North American Pancreatitis Study II (NAPS2) studies with the primary aim of 
comparing micronutrient antioxidant, bone metabolism, serum protein, and inflammatory 
marker levels between a clinically relevant and well characterized CP cohort and controls. 
Given the extent of pancreatic compromise evident in CP patients, we hypothesized the CP 
patients would demonstrate more signs of malabsorption and malnutrition than individuals 
without pancreatic disease. Secondarily, we evaluated these same biomarkers among 
subsets of CP patients, examining factors that might influence inflammatory and nutritional 
status, such as time since diagnosis, BMI, alcohol as the primary etiology of CP, diabetes 
mellitus, and PERT usage.  We analyzed the inflammatory biomarkers tumor necrosis factor 
alpha (TNF-α) and C-reactive protein (CRP), markers of inflammation and protein-calorie 
malnutrition serum prealbumin and RBP, nutritional variables vitamins A, D, E, and B12, and 
osteocalcin, a marker of bone turnover. Taken together, the insights gained from our study 
may provide better understanding of the effects of CP on nutrition and improve the process 
of assessing and optimizing the care of these patients.     
 
Methods 
Study cohort 
 CP patients and controls with no known pancreatic disease were ascertained 
from the North American Pancreatitis Studies, including the NAPS2-continuation and 
validation study (NAPS-CV) (2008-2012) and the NAPS2-AS (2011-2014). These studies 
were created following the success of the original NAPS2 study (2000-2006). Specific 
details of these studies have been published previously.9, 51, 52 In brief, a subset of all CP 
patients and controls from these two NAPS2 studies that had serum samples available 
using strict standard operating procedures (SOPs) were included in the current study. 
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Participants were recruited based on having adequate serum samples and 
questionnaire completion. Primary entry criteria for CP were predetermined, definitive 
evidence of CP on imaging studies, primarily either endoscopic retrograde 
cholangiopancreatography (ERCP) using the Cambridge classification or cross-sectional 
studies (computed tomography, magnetic resonance imaging/magnetic resonance 
cholangiopancreatography), and endoscopic ultrasound (five or more criteria or 
presence of calcifications) or histology. Controls were spouses, family members, friends, 
or individuals unrelated to CP patients; controls needed to be free from pancreatic 
diseases and capable of completing a survey and undergoing blood draw. Genomic DNA 
was initially extracted from whole blood using the Flexgene DNA® kit (Qiagen, Valencia, 
Calif., USA) with a modified manufacturer's buffy coat protocol. Serum was isolated 
from 10mL whole blood in non-additive serum tubes. Serum and a whole-blood sample 
were stored in a freezer at –80°C.  
 
Questionnaires 
Physician Questionnaire 
 Physician case report forms for CP patients were completed by a recognized 
expert in pancreatic diseases at participating centers, usually with the assistance of a 
clinical research coordinator. The information in the questionnaire was supplemented 
by medical record documentation of key diagnostic, laboratory, and hospital reports. 
Information that was queried focused on disease phenotype (e.g. history of acute 
pancreatitis, age at pancreatitis diagnosis, presence of morphological and functional 
abnormalities, etc.), etiology and risk factors, treatment received, and their perceived 
outcome.   
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Patient and Control Questionnaire 
 All CP patients and controls completed the participant questionnaire. The 
questionnaire included information on demographic factors including current and 
maximum height and weight (to calculate BMI), personal and family history of a variety 
of medical conditions, pancreatitis-related symptoms, disability and quality of life.  
Specific variables of interest for this study included age at enrollment, BMI, 
duration of disease (age at first symptoms or diagnosis of pancreatitis), physician-
defined alcohol etiology; current alcohol consumption; drinking category derived from 
self-reported drinking history during the maximum drinker period in life; smoking 
status [past, current, or never]; vitamin/mineral supplement use PERT use, and 
physician reporting of diabetes diagnosis. Participant drinking categories included – 
lifetime abstainer (<20 drinks during lifetime), light (up to 3 drinks a week), moderate 
(up to 7 drinks a week in women and 14 drinks in men), heavy (8-35 drinks a week in 
women, and 15-35 drinks a week in men) and very heavy (35 or more drinks a week in 
women and men).52 For the current manuscript, we combined heavy and very heavy 
drinking into one category. A number of controls (n=137) had missing information 
regarding drinking category, as they were enrolled in the NAPS2-CV and NAPS2-AS 
studies, when participant questionnaires for controls were abbreviated. Because 
participants took a large range of products, we used the broad term 
vitamin/supplement use (yes/no) as a covariate in analysis.  
 
Laboratory testing 
 We analyzed the inflammatory markers TNF-α and C-reactive protein (CRP) as 
well as osteocalcin using a Luminex platform.  An automated chemistry analyzer was 
used to measure levels of prealbumin; an enzyme-linked immunosorbent assay (ELISA) 
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to measure RBP; a microbiological microplate assay for vitamin B12; and high-
performance liquid chromatography (HPLC) to measure 25-OH Vitamin D3, vitamin E 
(α- and γ-tocopherol), and vitamin A. 
 
Statistical Methods  
 Descriptive statistics are presented as proportions for categorical and as mean ± 
standard deviation or median (interquartile range) for continuous data. The 
distributions of the levels of vitamins, nutritional/inflammatory markers, and indicators 
of bone turnover were assessed for normality using graphical methods and the Shapiro-
Wilks test. Correlation between continuous measures was assessed using Spearman’s 
correlation. Comparisons in discrete baseline characteristics between the CP patients 
and controls were performed using the chi-square test. Comparisons for continuous 
variables between the CP patients and controls, and within subset of patients and 
controls were through the Mann–Whitney U test.  Correlations between vitamin, 
nutrition, and biomarker levels were assessed using Spearman's rank correlation 
coefficient. To adjust for multiple comparisons, the Hommel’s procedure was adopted 
for calculating adjusted p-values.53     
 Multivariable linear regression models were created to determine independent 
factors that were predictive of the vitamin, nutrition and biomarker level outcomes. Due 
to the skewed nature of serum markers, logarithm transformation was applied to all 
serum markers except for vitamin E γ-tocopherol and TNF-α, for which square root 
function was applied such that the transformed levels approximated a normal 
distribution. The log or square root transformed micronutrient and inflammatory 
marker values were included as the dependent variable in the multivariable models, 
and factors retained in the models as covariates, included diagnosis, age, gender, race, 
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BMI, alcohol consumption, smoking status, and supplemental vitamin intake. Interaction 
term between race and diagnosis as well as sex and age were also included in the full 
model. Other first order interactions were also tested, but due to minimal changes in the 
model performance (i.e. in R2) in some of the outcome variables, we have chosen to 
show simplified models with interaction term for race and diagnosis, and sex and age. 
No higher order interactions were examined due to the complexity of model 
interpretation. Separate multivariable analyses were also performed for CP patients 
only, where, in addition to the aforementioned variables, PERT use and diabetes status 
were also included as covariates. Backward stepwise selection was used for variable 
selection with a P value cutoff of p <0.20 used for incorporation into the model while a P 
value of less than 0.05 was considered significant. For interpretation of the model, 
square root and log transformed data may be reverse transformed using a square or 
exponential function respectively to bring the data back to the original units with the 
understanding that not all components of the model (error terms, confidence intervals, 
etc.) will be correct in native units. Conversely, the coefficients in the log-transformed 
models correspond the percent change in the mean of the outcome variables.  All 
statistical analysis was performed using the R Project software (www.r-project.org). 
 
Results 
Cohort 
 The final sample included 301 eligible CP patients and 266 controls (Table 1). 
When compared with controls, CP patients were significantly (p<0.05) older (50.8 vs. 
45.6 years), male (50.1 vs. 40.2%), Caucasian (71.1 vs. 58.3%), past or current smokers 
(77.7 vs. 51.1%), and taking vitamin supplements (55.8 vs. 45.1%). CP patients were 
less likely to be current drinkers (20.6 vs. 66.2%), and amongst participants with 
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available information, more likely to be heavy or very heavy drinkers (53.3 vs. 34.2%).   
CP patients were less likely to be overweight (25.9% vs. 36.5%) or obese (18.6% vs. 
38.3%.) when compared with controls. Twenty-two of the 266 (9%) controls reported 
being diabetic (data not shown). 
 Among patients with CP, almost half (49.8%) had physician-defined alcohol 
etiology for their illness and more than one-third (38.5%) were identified as having 
diabetes per the enrolling physician. Just over one-half (55.1%) of CP patients were 
using PERT. About three-quarters (73.3%) of CP patients had a disease duration that 
was <5 years (Table 2). 
   
Vitamin, nutrition and biomarker levels  
Internal Validation 
 Several previously described relationships between biomarkers were evaluated 
as internal validation of the data.5, 54-57 CP patients had significantly lower BMI than 
control patients, with 44.5% of CP patients being overweight or obese compared to 
74.8% of controls (Table 1).  Amongst all study participants (controls and CP patients), 
CRP levels correlated positively with BMI. Additionally, for all participants, there was a 
strong correlation between RBP and vitamin A levels (correlation 0.88, 0.89), between 
prealbumin and RBP (0.73, 0.70), and between prealbumin and vitamin A levels (0.72, 
0.75).  There were weaker positive correlations between fat-soluble vitamins A and E [α 
–tocopherol] (0.50, 0.58), and vitamins A and D3 (0.26, 0.34). 
 
Effect of CP on vitamin and biomarker levels 
 Serum levels of vitamins, nutritional markers, and inflammatory biomarkers in 
CP patients and controls are provided in Table 3. After correcting for multiple 
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comparisons, CP patients had significantly lower levels of vitamin A (40.9 vs. 45.4 
µg/dL) and vitamin E (both α- [8.7 vs. 10.3 mg/L] and γ- [1.8 vs. 2.2 mg/L] tocopherol), 
as well as osteocalcin (7.9 vs. 10 ng/ml) and prealbumin 23 vs. 27 mg/dL), than 
controls. The median level of Vitamin B12 was significantly higher in CP patients when 
compared with controls (703 vs. 609.5 pg/mL). CP patients also had a significantly 
higher level of CRP than controls (0.3 vs. 0.2 mg/dL).  Table 3 also shows the number 
and percentage of study participants that demonstrated vitamin and nutritional marker 
deficiencies according to standard laboratory thresholds. Compared to controls, a 
higher percentage of CP patients had deficiencies in vitamins A, D, and the α-tocopherol 
component of vitamin E, although the discrepancy between controls and CP patients for 
vitamin D was less pronounced.  A greater proportion of patients than controls had 
lower levels of osteocalcin, and showed deficiencies in prealbumin and RBP with 
marked differences in rates of deficiency being noted for prealbumin (15.3% of CP 
patients showed deficiency vs. 2.3% of controls). 
 
Effect of treatment with PERT and/or vitamin supplements 
 Among patients with CP, when compared with patients who were not on PERT, 
those receiving PERT had significantly higher levels of Vitamin A (median 43.3 vs. 36.6 
µg/dl), prealbumin (median 24 vs. 22 mg/dl), and a trend towards higher levels of RBP 
(median 36.3 vs. 32.5 µg/dl) (Supplementary Table 1).   
When compared with CP patients that were not taking vitamin supplements, 
those on supplements had significantly higher levels of vitamin A (median 45.0 vs. 38.3 
µg/dl), α -tocopherol (9.5 vs. 8.0 mg/L) and γ-tocopherol (1.56 vs. 2.2 mg/L), and 
borderline higher levels of vitamin B12 (756.5 vs. 649 pg/ml) and RBP (36.3 vs. 32.2 
µ/ml) (Supplementary table 2). No significant differences were noted in the serum 
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levels of vitamins, nutritional markers, or biomarkers based on alcohol etiology or 
disease duration although a trend was observed for lower levels of prealbumin in CP 
patients with diabetes when compared to non-diabetic CP patients (data not shown).  
 Similarly, when compared with controls that were not taking vitamin 
supplements, controls that used supplements had significantly higher levels of vitamin 
B12 (median 653 vs. 587 pg/ml), vitamin D (27.2 vs. 16.1 ng/ml), α-tocopherol (11.60 
vs. 9.70 mg/L) and a trend towards significantly higher levels of vitamin A (47.9 vs. 44 
µg/dl) (Supplementary Table 3).  
 
Multivariable regression models to assess the effect of CP and other co-factors on 
serum vitamins, nutrition and biomarkers 
Independent predictors for serum levels of vitamins, nutritional markers and 
biomarkers in controls and CP patients are shown in Table 4.  In this analysis, 
interpretation of parameter estimates for each of the covariates quantifies the 
independent effect of an attribute versus the comparison group (e.g. CP vs. controls) 
after adjusting for other variables. A positive parameter estimate suggests higher levels, 
while a negative parameter estimate indicates lower levels in reference to the 
comparison group.  
After controlling for other factors, when compared with controls, CP patients had 
significantly lower levels of vitamins A and E (both α- and ϒ-tocopherol), but 
significantly higher levels of vitamin B12. CP patients also had significantly lower levels 
of osteocalcin, prealbumin and RBP. Additionally, CRP levels were significantly higher in 
CP patients compared to controls, suggesting that patients had increased systemic 
inflammation.  As an example, the interpretation of parameter estimates for CRP will be 
that, on average, CRP levels in patients with CP are 0.681 mg/dL higher when compared 
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with controls, after adjusting for other co-variates. A similar interpretation would be 
applicable for vitamins and other biomarkers, taking into consideration whether the 
parameter estimate has a positive or negative value. 
 
Effects of demographics 
The study cohort included a sufficient number of Caucasian (white) and African-
American (black) patients for comparative analysis. When compared with Caucasians, 
African-Americans had significantly lower levels of vitamin D, α-tocopherol, and RBP.  
An interaction was noted between race and diagnosis for several vitamins and 
biomarkers. Lower levels of vitamin A and prealbumin levels in CP patients versus 
controls were observed among African-Americans study participants to a greater 
degree than among Caucasian participants. The increment of baseline levels of CRP in 
CP patients from controls is more evident in African-Americans than that in Caucasians. 
The interaction between diagnosis and race for vitamin B12 and TNF-a was interesting. 
Overall, African-American controls had significantly higher vitamin B12 levels when 
compared with Caucasian controls; however, there was no racial difference in vitamin 
B12 levels among CP patients. While TNF-α did not show a significant difference 
between Caucasian CP patients and Caucasian controls, it was significantly elevated in 
African-American CP patients when compared with African-American controls.  
Significant associations with sex, age, BMI, alcohol and tobacco use were noted 
for a few comparisons (Table 4). Other than diagnosis and race, the only other clinically 
relevant interaction was noted between sex and age for osteocalcin levels – i.e. with 
increasing age, the level of osteocalcin decreased in males.   
 
Effect of vitamin and PERT supplementation 
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Vitamin supplementation was associated with significantly higher levels of 
Vitamin A, D, E α-tocopherol, and B12, but not E ϒ-tocopherol.  We evaluated the 
independent effect of PERT usage on serum vitamins, nutritional markers and 
biomarkers in regression models limited to CP patients only (Supplementary Table 4). 
PERT usage was associated with a significant increase in serum levels of vitamins A and 
ϒ-tocopherol and nutritional markers including RBP and prealbumin.  
 
Discussion 
Our study is the first of its kind to evaluate various nutritional and inflammatory 
markers in a sizeable, racially diverse group of CP patients and controls.  The study is 
especially relevant as it reflects a cross-sectional assessment of the state of hundreds of 
well-characterized patients who are receiving care at pancreas disease centers across 
the United States.  We assessed various parameters of nutritional status and 
inflammation amongst 301 CP patients and 266 controls. Previous studies of nutritional 
status are limited in number and have not factored in alcohol as an etiology, BMI, 
diabetes, vitamin/mineral supplementation and the use of PERT.  Additionally, we are 
not aware of any U.S. studies that have examined whether race may play a role in the 
nutritional status of individuals who carry a diagnosis of CP. 
Expected baseline differences between CP patients and controls included lower 
BMI, being current or previous smokers, taking vitamin supplements, and not being 
current drinkers.  These effects were notable, since the duration of CP was fewer than 5 
years in the majority of CP patients. Patients with a history of alcoholic CP did not have 
significantly different levels of nutritional markers than patients with other etiologies of 
CP.  Counseling regarding the deleterious effects of alcohol may have accounted for 
fewer CP patients being current drinkers compared with controls. Nonetheless, even 
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after adjusting for multiple confounders and multiple comparisons, significant 
differences between patients and controls and certain subsets of participants existed. 
Although the majority of patients in our study had been diagnosed with a chronic form 
of pancreatitis within 5 years of entering the study, most CP patients were using PERT.  
Steatorrhea and its associated symptoms are often the primary indicators for the need 
to prescribe PERT. However, steatorrhea may develop a decade after the diagnosis of CP 
but it can also be present at the time of diagnosis. According to the United European 
Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic 
pancreatitis (HaPanEU), all newly diagnosed CP patients should be screened for 
pancreatic enzyme insufficiency.58 When patient symptoms are not definitive, the 
guidelines advocate a 4-6 week trial of PERT. 
 Diminished symptoms of maldigestion (e.g. weight loss, flatulence, bloating, 
steatorrhea) and improvements in nutritional status reflect the efficacy of PERT.58 A 
more recent diagnosis in a sizeable number of patients as well as PERT use likely 
explains similar serum micronutrient levels in CP patients using PERT when compared 
with those who were not taking PERT.  Similarly, use of vitamin supplements in both 
controls and CP patients resulted in higher levels of certain vitamins or vitamin sub-
units than in participants who did not supplement their diet.  
 
Nutritional markers 
The major form of vitamin E present in the diet of individuals living in the United 
States is ϒ-tocopherol, although α-tocopherol is the form found in human tissues as well 
as dietary supplements.59 Our study found that CP patients had significantly lower 
levels of vitamin A and both forms of vitamins E (α- and ϒ-tocopherol) than controls 
although vitamin supplementation and PERT influenced these differences.  A recent 
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meta-analysis by Martinez-Moneo et al. evaluated fat-soluble vitamin deficiency in CP 
patients.33 Among four studies that included161 patients, the pooled prevalence of 
vitamin A deficiency was 16.8% (95% CI, 6.9- 35.7%) and of vitamin E deficiency was 
29.2% (95% CI 8.6 - 64.5%).42, 45, 60, 61 
A 2014 study by Duggan et al. noted that 14.5% and 24.2% of CP patients had 
deficiencies in the fat-soluble vitamins A and E, respectively, although half of the 
patients in this study were either overweight or obese.60 They also found that 19% of 
their patients had high serum levels of vitamin A. In our study, 74.8% of controls and 
44.5% of CP patients were overweight or obese according to BMI. This large proportion 
of overweight or obese study participants raises the question of whether any 
participants had high levels of vitamins A or E. We found no correlations between 
overweight/obesity and elevated levels of vitamins A or E. Two CP patients had vitamin 
A levels in the toxic range (>120.0 mcg/dL) and both patients had normal BMI (21.1 and 
23.0 m2/kg). Just three CP patients had elevated vitamin E (α-tocopherol), two of whom 
were overweight (BMI of 26.5, and 28.7 m2/kg) while one had normal BMI (23.8 
m2/kg). All CP subjects with an elevated vitamin A or E were taking vitamin 
supplements. No controls had elevated vitamin A or vitamin E levels regardless of 
supplement use. These data were not presented in our results due to the minimal 
number of patients with elevations and their lack of association with BMI. While the 
comparatively lower levels of fat-soluble vitamins A and E, and RBP in CP patients 
versus controls in our study may indicate that patients may require supplementation to 
reach adequate levels, a small number of patients may be taking an excessive dose of 
vitamins A or E. Universal or indiscriminate vitamin supplementation for individuals 
with CP is not advisable.58 Each patient should be evaluated individually for vitamin 
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deficiencies and appropriate supplementation should be recommended when dietary 
intake is inadequate to address nutritional deficits. 
Osteopenia occurs when bone breakdown exceeds bone formation leading to 
lower bone mass. Diminished bone mass is a critical risk for morbidity in patients with 
CP.30   We evaluated osteocalcin levels as a measure of osteoblast activity during bone 
formation with serum concentrations serving as a biochemical marker for bone 
formation.62 Previous studies have noted low osteocalcin levels in CP patients.47 Serum 
osteocalcin levels decline with age, reflecting decreased bone formation and turnover.63 
Osteocalcin may also function as a metabolic hormone, with multiple beneficial effects 
on glucose and fat metabolism.62 Studies have shown that serum osteocalcin levels are 
associated with glucose and lipid metabolism in men and women, and lower levels have 
been shown to correlate to diabetes and metabolic syndrome.64-66 In multivariable 
comparisons, osteocalcin levels were significantly lower in CP patients than controls.  In 
regression analyses, there were no differences in osteocalcin levels in men and women.  
In adjusted analyses, levels of vitamin D and osteocalcin were lower in CP patients than 
in controls. Close to 40% of our CP patients had diabetes according to their physicians, 
compared to 9% self-reported by our controls. The high rate of diabetes in our patients, 
in part, may have accounted for their low osteocalcin levels. Vitamin D levels amongst 
all study participants were lower in African-Americans than in Caucasians.  
Vitamin D is naturally present in a few foods, added to others, available as a 
dietary supplement, and produced endogenously when sunlight’s ultraviolet rays strike 
the skin and trigger vitamin D synthesis.67 Individuals with inadequate vitamin D 
absorption are at risk for all forms of osteopathy and have a significantly elevated 
likelihood of sustaining bone fractures.68, 69 Given the high morbidity and mortality 
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associated with fractures in older individuals, and previous findings of osteopathy 
amongst CP patients, vitamin D supplementation is advisable.30, 49, 70  
An unexpected finding was modestly higher vitamin B12 levels in patients with 
CP than controls, with or without oral vitamin supplementation. Vitamin B12 is a 
dietary vitamin that binds to R-proteins in the stomach to form a B12-R complex.71    
Intrinsic factor (IF) synthesized by the stomach’s parietal cells is secreted into the 
duodenum, where proteases secreted from the pancreas digest the R-proteins and 
release B12, which then binds to IF to form a B12-IF complex.71, 72 Receptors on 
enterocytes in the terminal ileum are only able to recognize the B12-IF complex; 
therefore, the two must be bound to be absorbed.72 Thus, vitamin B12 deficiency occurs 
in CP patients as a consequence of protease deficiency.73 Although the majority of both 
CP patients and controls had normal range vitamin B12 levels, CP patients may have 
been receiving B12 injections, bypassing the gastrointestinal track altogether.  This 
potential explanation cannot be confirmed because a history of B12 injections was not 
included in the NAPS2 case report forms. However, 20.3% of CP patients had a serum 
vitamin B12 level above 1000 pg/mL, which may indicate that they were receiving B12 
injections (data not shown). By comparison, only 10.5% of controls had a serum vitamin 
B12 that surpassed 1000 pg/mL.  
 
Inflammatory markers 
 CP exemplifies a chronic inflammatory disorder, but the amount and type of 
inflammation that a CP patient experiences at any specific time is typically unknown. 
Although inflammation plays a critical role in CP, the inflammation can be episodic or 
continuous while the disease itself is defined by morphology, pain and diminishing 
exocrine function in later stages.   These features are not surrogates of each other.74, 75 
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Therefore, these factors should be assessed in relation to disease activity, progression 
and response to treatment.76 
  Previous research has focused on serum biomarkers of inflammation in 
pancreatitis linked to different outcomes and demonstrated that inflammation has a 
wide impact.  For example, Rasch et al. conducted a systematic review of studies that 
measured inflammatory mediators in CP to determine the association between chronic 
inflammation, early mortality, and markers of accelerated biological aging, or 
"inflammageing."77 Beyer et al. demonstrated that CRP, hemoglobin A1c, BMI, platelet 
count, and pain score were strong predictors of future hospitalization and length of 
stay.75   An inverse correlation between log of CRP level and bone mineral density in 
patients with CP was noted by Duggan et al, suggesting that bone turnover is affected by 
systemic inflammation.70 A study by Mroczko et al. demonstrated that both IL-6 and 
CRP levels are slightly but significantly higher in CP patients compared to controls, but 
markedly higher in patients with pancreatic cancer, with levels correlating with cancer 
stage.78 Thus, systemic inflammation, as reflected by serum CRP levels, correlates with 
CP morbidity in systems outside the pancreas.  Herein we extend these findings to a 
large, well-phenotyped cohort of CP patients with biomarkers of both nutrition and 
inflammation. 
 TNF-
some patients with CP were recruited during episodes of acute pancreatitis, which likely 
contributed to markedly elevated levels in a very small number of patients.  CRP is an 
acute phase reactant produced by the liver in response to inflammation. Normal CRP 
levels are 3.0 mg/L (or 0.3 mg/dL) or less, requiring high sensitivity CRP testing for 
accurate measurement.  CRP levels increased with BMI (Table 4), with obesity 
representing a known pro-inflammatory condition.79 We confirmed that CRP levels are 
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elevated in CP patients versus controls (Table 3), with CRP levels in our cases being 
similar to those noted by Duggan et al. (mean 3.0 vs. 3.15 mg/L), while levels in in our 
controls were higher (mean 2.0 vs. 0.9 mg/L).70 Although our controls lacked pancreatic 
disease, they may have had other illnesses.  CRP levels may be elevated due to chronic 
diseases and advancing age, with progressive increases being observed amongst 
individuals with multiple co-morbidities.80, 81 The U.S. National Health and Nutrition 
Examination Survey (NHANES) cohort, for example, estimated multi-morbidity in 
36.7% of adult Americans.82 Compared to our CP patients, CRP levels in the NHANES 
cohort were 2.65 +/− 0.11 for controls, 3.92 +/− 0.11, for individuals with one chronic 
disease and 5.80 +/− 0.12 for the multi-morbidity cohort, including patients with 
asthma, arthritis, chronic liver disease, COPD, kidney failure, obesity and history of 
cancer – with obesity being a major contributor to elevation. CRP levels are often 
analyzed in conjunction with albumin levels to generate the Glasgow Prognostic Scores 
(GPS), a measure of chronic inflammation and a strong prognostic factor for survival in 
various cancers.82 The severity score increases with CRP > 10 mg/L, a value that was 
rarely seen in our cohort. Therefore, the GPS is unlikely to be a useful marker of chronic 
inflammation in CP, except in extreme cases.  Similar to albumin, prealbumin may be 
diminished due to inflammation. The lower levels of prealbumin in our CP patients were 
likely to be a stronger reflection of systemic inflammation than protein-calorie 
malnutrition.17,18  
Our study has numerous strengths. The study's large sample size could detect 
small differences in nutritional and inflammatory biomarker levels. Additionally, 
patients, patients’ physicians, and controls each completed detailed questionnaires that 
resulted in well-defined CP etiology for patients and comprehensive information 
regarding lifestyle habits for all participants. Our serum samples were processed using 
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meticulous SOPs, providing results that are likely to be accurate and reliable. 
Weaknesses of the study include the fact that our patients and controls were not 
precisely matched, with the median age of patients being 5 years older than controls 
and 50% of patients compared to 40% of controls being male. Advancing age may be 
associated with a decline in nutritional status due to medical, psychological, social, and 
other factors, such as limited food access.83 Therefore, differences in nutritional 
markers may have reflected older age as well as disease status. Additionally, the NAPS2 
study centers are tertiary care institutions. CP patients who have been evaluated at 
highly skilled centers may be diagnosed earlier and receive more comprehensive care, 
which could be reflected by the relatively high percentage of patients taking PERT, 
refraining from alcohol consumption, and using dietary supplements. Therefore, our 
findings may have been attenuated compared to the general population of CP patients. 
The type of vitamin supplementation used by study subjects varied widely from single 
vitamin (e.g. vitamin B12 or vitamin D) formulations to multivitamin preparations with 
various quantities of different vitamins, minerals and other nutriceuticals. The majority 
used combination products. Due to the vast array of ingredients and quantities ingested, 
we considered subjects using any form of supplement into the vitamin supplementation 
category. Our binary classification of supplement use may have impacted our 
conclusions. Finally, we were missing data for some lifestyle variables.   
Overall, inflammatory markers were generally increased in CP patients and 
micronutrient levels were generally lower in CP patients when compared to controls, 
with CP patients showing higher rates of micronutrient deficiencies.  The physician-
defined etiology of alcohol does not appear to have a significant effect on the status of 
protein nutrition or micronutrients.  Measures of protein nutrition and levels of 
micronutrients were clearly associated with vitamin supplementation and the use of 
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PERT.  This indicates that PERT may help to minimize protein and vitamin deficiencies 
associated with CP, regardless of etiology, and therefore improve patients’ 
micronutrient status. Our study also demonstrated that there are potential racial 
differences in nutrient and inflammatory markers, indicating the need for future studies 
of mechanisms and therapies. 
 
References: 
1. Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, et al. Chronic 
pancreatitis: An international draft consensus proposal for a new mechanistic 
definition. Pancreatology. 2016;16(2):218-24. 
 
2. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Eng J Med. 
1995;332:1482-90. 
 
3. Worning H. Chronic pancreatitis: pathogenesis, natural history and conservative 
treatment. Clin Gastroenterol. 1984;13:871-94. 
 
4. Lankisch PG. Natural course of chronic pancreatitis. Pancreatology 2001;1:3-14. 
 
5. Nakamura T, Takebe K, Imamura K, Tando Y, Yamada N, Arai Y, et al. Fat-soluble 
vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Acta 
Gastroenterol Belg. 1996;59(1):10-4. 
 
6. Pasanen AV, Tarpila S, Miettinen TA. Relationships between serum lipids and 
malabsorption of bile acids, neutral sterols, and fats in exocrine pancreatic 
insufficiency. Scand J Gastroenterol. 1980;15:503-7. 
 
7. Petersen JM, Forsmark CE. Chronic pancreatitis and maldigestion. Semin 
Gastrointest Dis. 2002;13:191-9. 
 
8. Whitcomb DC, Bodhani A, Beckmann K, Sander-Struckmeier S, Liu S, Fuldeore M, 
et al. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine 
Pancreatic Insufficiency and a Medical History of Diabetes Mellitus. Pancreas 
2016;45:679-86. 
 
9. Yadav D, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA, et al. Alcohol 
consumption, cigarette smoking, and the risk of recurrent acute and chronic 
pancreatitis.[Erratum appears in Arch Intern Med. 2011 Apr 11;171(7):710]. 
Arch Intern Med 2009;169:1035-45. 
 
  
 
This article is protected by copyright. All rights reserved. 
 
24 
10. Mokrowiecka A, Pinkowski D, Malecka-Panas E, Johnson CD. Clinical, emotional 
and social factors associated with quality of life in chronic pancreatitis. 
Pancreatology 2010;10:39-46. 
 
11. Jensen GL. Malnutrition and inflammation-"burning down the house": 
inflammation as an adaptive physiologic response versus self-destruction? JPEN J 
Parenter Enteral Nutr. 2015;39:56-62. 
12. Johnson AM. Low levels of plasma proteins: malnutrition or inflammation? Clin 
Chem Lab Med 1999;37:91-6. 
 
13. Yamada S, Tokumoto M, Tatsumoto N, Tsuruya K, Kitazono T, Ooboshi H. Very 
low protein diet enhances inflammation, malnutrition, and vascular calcification 
in uremic rats. Life Sci. 2016;146:117-23. 
 
14. Lasztity N, Biro L, Nemeth E, Pap A, Antal M, Lasztity N, et al. Protein status in 
pancreatitis--transthyretin is a sensitive biomarker of malnutrition in acute and 
chronic pancreatitis. Clin Chem Lab Med. 2002;40:1320-4. 
 
15. Schrader H, Menge BA, Belyaev O, Uhl W, Schmidt WE, Meier JJ, et al. Amino acid 
malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. 
Pancreas 2009;38:416-21. 
 
16. Bharadwaj S, Ginoya S, Tandon P, Gohel TD, Guirguis J, Vallabh H, et al. 
Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep. 
2016;4:272-280. 
 
17. White JV, Guenter P, Jensen G, Malone A, Schofield M. Consensus statement of the 
Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral 
Nutrition: characteristics recommended for the identification and 
documentation of adult malnutrition (undernutrition). J Acad Nutr Diet. 
2012;112:730-8. 
 
18. McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, 
et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy 
in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and 
American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J 
Parenter Enteral Nutr. 2016;40:159-211. 
 
19. Verlaan M, Roelofs HM, van-Schaik A, Wanten GJ, Jansen JB, Peters WH, et al. 
Assessment of oxidative stress in chronic pancreatitis patients. World J 
Gastroenterol. 2006;12:5705-10. 
 
20. Shen J, Lai CQ, Mattei J, Ordovas JM, Tucker KL, Shen J, et al. Association of 
vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory 
conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr. 2010;91:337-
42. 
 
  
 
This article is protected by copyright. All rights reserved. 
 
25 
21. Braganza JM, Schofield D, Snehalatha C, Mohan V. Micronutrient antioxidant 
status in tropical compared with temperate-zone chronic pancreatitis. Scand J 
Gastroenterol. 1993;28:1098-104. 
 
22. Quilliot D, Walters E, Bohme P, Lacroix B, Bonte JP, Fruchart JC, et al. Fatty acid 
abnormalities in chronic pancreatitis: effect of concomitant diabetes mellitus. 
Eur J Clin Nutr. 2003;57:496-503. 
 
23. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, et al. Total and 
cancer mortality after supplementation with vitamins and minerals: follow-up of 
the Linxian General Population Nutrition Intervention Trial. J Natl Cancer 
Inst.101(7):507-18. 
 
24. Reyes-Ortiz CA, Ju H, Inniss A, Eschbach K, Kuo YF, Goodwin JS, et al. 
Acculturation and serum nutrients thought to be involved with cancer 
prevention among Mexican American men in the United States. Cancer Control. 
2009;16:169-75. 
 
25. Pelucchi C, Tramacere I, Bertuccio P, Tavani A, Negri E, La Vecchia C. Dietary 
intake of selected micronutrients and gastric cancer risk: an Italian case-control 
study. Ann Oncol.  2009;20:160-5. 
 
26. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency 
with hypertriglyceridemia and pancreatitis. N Eng J Med.  1978;299:1421-4. 
 
27. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: 
functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb 
Vasc Biol.  1999;19:472-84. 
 
28. Simon P, Weiss FU, Zimmer KP, Koch HG, Lerch MM. Acute and chronic 
pancreatitis in patients with inborn errors of metabolism. Pancreatology 
2001;1:448-56. 
 
29. Blecker U, Mehta DI, duPont AI, Davis R, Sothern MS, Suskind RM. Fat-soluble 
vitamin deficiencies. Pediatrics in Review 1999;20:394-5. 
 
30. Dujsikova H, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of 
metabolic osteopathy in patients with chronic pancreatitis. Pancreatology 
2008;8:583-6. 
 
31. Nakamura T, Takebe K, Imamura K, Arai Y, Kudoh K, Terada A, et al. Changes in 
plasma fatty acid profile in Japanese patients with chronic pancreatitis. J Int Med 
Res. 1995;23:27-36. 
 
32. Vaona B, Armellini F, Bovo P, Rigo L, Zamboni M, Brunori MP, et al. Food intake of 
patients with chronic pancreatitis after onset of the disease. Am J Clin Nutr. 
1997;65:851-4. 
  
 
This article is protected by copyright. All rights reserved. 
 
26 
33. Martinez-Moneo E, Stigliano S, Hedstrom A, Kaczka A, Malvik M, Waldthaler A, et 
al. Deficiency of fat-soluble vitamins in chronic pancreatitis: A systematic review 
and meta-analysis. Pancreatology 2016;16:988-994. 
 
34. Teichmann J, Mann ST, Stracke H, Lange U, Hardt PD, Klor HU, et al. Alterations of 
vitamin D3 metabolism in young women with various grades of chronic 
pancreatitis. Eur J Med Res. 2007;12:347-50. 
 
35. Duggan SN, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High 
prevalence of osteoporosis in patients with chronic pancreatitis: a systematic 
review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:219-28. 
 
36. Mann ST, Stracke H, Lange U, Klor HU, Teichmann J, Mann STW. Alterations of 
bone mineral density and bone metabolism in patients with various grades of 
chronic pancreatitis. Metab Clin Exp.  2003;52:579-85. 
 
37. Mann ST, Stracke H, Lange U, Klor HU, Teichmann J. Vitamin D3 in patients with 
various grades of chronic pancreatitis, according to morphological and functional 
criteria of the pancreas. Dig Dis Sci. 2003;48:533-8. 
 
38. Peterlik M, Cross HS. Vitamin D and calcium insufficiency-related chronic 
diseases: molecular and cellular pathophysiology. Eur J Clin Nutr. 2009;63:1377-
86. 
 
39. Layer P, Keller J, Lankisch PG. Pancreatic enzyme replacement therapy. Curr 
Gastroenterol Rep. 2001;3:101-8. 
 
40. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and 
perspectives. Pancreas 2003;26:1-7. 
 
41. Dominguez-Munoz JE, Iglesias-Garcia J, Vilarino-Insua M, Iglesias-Rey M. 13C-
mixed triglyceride breath test to assess oral enzyme substitution therapy in 
patients with chronic pancreatitis. Clin Gastroenterol Hepatol .  2007;5:484-8. 
 
42. Dutta SK, Bustin MP, Russell RM, Costa BS. Deficiency of fat-soluble vitamins in 
treated patients with pancreatic insufficiency. Ann Intern Med 1982;97:549-52. 
 
43. Trolli PA, Conwell DL, Zuccaro G, Jr. Pancreatic enzyme therapy and nutritional 
status of outpatients with chronic pancreatitis. Gastroenterol Nurs.  2001;24:84-
7. 
 
44. Segal I, Gut A, Schofield D, Shiel N, Braganza JM. Micronutrient antioxidant status 
in black South Africans with chronic pancreatitis: opportunity for prophylaxis. 
Clinica Chimica Acta 1995;239:71-9. 
 
45. Sikkens EC, Cahen DL, Koch AD, Braat H, Poley JW, Kuipers EJ, et al. The 
prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in 
patients with chronic pancreatitis. Pancreatology 2013;13:238-42. 
 
  
 
This article is protected by copyright. All rights reserved. 
 
27 
46. Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D 
supplementation in patients suffering from chronic pancreatitis and pancreatic 
cancer disease. Anticancer Research 2012;32:1991-8. 
 
47. Pezzilli R, Melzi d'Eril GV, Barassi A. Markers of Bone Metabolism in Patients 
With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma. Medicine 
(Baltimore) 2015;94:e1754. 
 
48. Moran CE, Sosa EG, Martinez SM, Geldern P, Messina D, Russo A, et al. Bone 
mineral density in patients with pancreatic insufficiency and steatorrhea. Am J 
Gastroenterol 1997;92:867-71. 
 
49. Prabhakaran A, Bhasin DK, Rana SS, Bhadada SK, Bhansali A, Rao C, et al. Bone 
mineral metabolism and bone mineral density in alcohol related and idiopathic 
chronic pancreatitis. Trop Gastroenterol 2014;35:107-12. 
 
50. Nicolas JM, Estruch R, Antunez E, Sacanella E, Urbano-Marquez A. Nutritional 
status in chronically alcoholic men from the middle socioeconomic class and its 
relation to ethanol intake. Alcohol & Alcoholism 1993;28:551-8. 
 
51. Yadav D, Slivka A, Sherman S, Hawes RH, Anderson MA, Burton FR, et al. Smoking 
is underrecognized as a risk factor for chronic pancreatitis. Pancreatology 
2010;10:713-9. 
 
52. Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, et al. 
Multicenter approach to recurrent acute and chronic pancreatitis in the United 
States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology 
2008;8:520-31. 
 
53. Hommel G. A stagewise rejective multiple test procedure based on a modified 
Bonferroni test. Biometrika 1988; 75 (2): 383-386. doi: 
10.1093/biomet/75.2.383. 
 
54. Baeten JM, Richardson BA, Bankson DD, Wener MH, Kreiss JK, Lavreys L, et al. 
Use of serum retinol-binding protein for prediction of vitamin A deficiency: 
effects of HIV-1 infection, protein malnutrition, and the acute phase response. 
Am J Clin Nutr. 2004;79:218-25. 
55. Bauernfeind JC, Newmark H, Brin M. Vitamins A and E nutrition via 
intramuscular or oral route. Am J Clin Nutr. 1974;27:234-53. 
 
56. O'Doherty MG, Jorgensen T, Borglykke A, Brenner H, Schottker B, Wilsgaard T, et 
al. Repeated measures of body mass index and C-reactive protein in relation to 
all-cause mortality and cardiovascular disease: results from the consortium on 
health and ageing network of cohorts in Europe and the United States 
(CHANCES). Eur J Epidemiol.  2014;29:887-97. 
 
57. Rode L, Nordestgaard BG, Weischer M, Bojesen SE. Increased body mass index, 
elevated C-reactive protein, and short telomere length. J Clin Endocrinol Metab. 
2014;99:E1671-5. 
  
 
This article is protected by copyright. All rights reserved. 
 
28 
 
58. Lohr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et 
al. United European Gastroenterology evidence-based guidelines for the 
diagnosis and therapy of chronic pancreatitis (HaPanEU). United European 
Gastroenterol J 2017;5:153-199. 
 
59. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form 
of vitamin E in the US diet, deserves more attention. Am J Clin Nutr 2001;74:714-
22. 
 
60. Duggan SN, Smyth ND, O'Sullivan M, Feehan S, Ridgway PF, Conlon KC. The 
prevalence of malnutrition and fat-soluble vitamin deficiencies in chronic 
pancreatitis. Nutr Clin Pract. 2014;29:348-54. 
 
61. Marotta F, Labadarios D, Frazer L, Girdwood A, Marks IN. Fat-soluble vitamin 
concentration in chronic alcohol-induced pancreatitis. Relationship with 
steatorrhea. Dig Dis Sci 1994;39:993-8. 
 
62. Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine 
functions. Biochem Pharmacol 2017. 
 
63. Vanderschueren D, Gevers G, Raymaekers G, Devos P, Dequeker J. Sex- and age-
related changes in bone and serum osteocalcin. Calcif Tissue Int 1990;46:179-82. 
 
64. Chen L, Li Q, Yang Z, Ye Z, Huang Y, He M, et al. Osteocalcin, glucose metabolism, 
lipid profile and chronic low-grade inflammation in middle-aged and elderly 
Chinese. Diabetic Medicine 2013;30:309-17. 
 
65. Confavreux CB, Szulc P, Casey R, Varennes A, Goudable J, Chapurlat RD. Lower 
serum osteocalcin is associated with more severe metabolic syndrome in elderly 
men from the MINOS cohort. Eur J Endocrinol. 2014;171:275-83. 
 
66. Lumachi F, Orlando R, Fallo F, Basso SM. Relationship between bone formation 
markers bone alkaline phosphatase, osteocalcin and amino-terminal propeptide 
of type I collagen and bone mineral density in elderly men. Preliminary results. 
In Vivo 2012;26:1041-4. 
 
67. DeLuca HF. Overview of general physiologic features and functions of vitamin D. 
Am J Clin Nutr. 2004;80:1689S-96S. 
 
68. Cauley JA, Lui LY, Genant HK, Salamone L, Browner W, Fink HA, et al. Risk factors 
for severity and type of the hip fracture. J Bone Miner Res.  2009;24:943-55. 
 
69. Radcliff TA, Henderson WG, Stoner TJ, Khuri SF, Dohm M, Hutt E, et al. Patient 
risk factors, operative care, and outcomes among older community-dwelling 
male veterans with hip fracture. J Bone Joint Surg Am.  2008;90:34-42. 
 
70. Duggan SN, Purcell C, Kilbane M, O'Keane M, McKenna M, Gaffney P, et al. An 
association between abnormal bone turnover, systemic inflammation, and 
  
 
This article is protected by copyright. All rights reserved. 
 
29 
osteoporosis in patients with chronic pancreatitis: a case-matched study. Am J 
Gastroenterol 2015;110:336-45. 
 
71. Gueant JL, Djalali M, Aouadj R, Gaucher P, Monin B, Nicolas JP. In vitro and in vivo 
evidences that the malabsorption of cobalamin is related to its binding on 
haptocorrin (R binder) in chronic pancreatitis. Am J Clin Nutr.  1986;44:265-77. 
 
72. Srikumar K, Premalatha R. Effect of gastrointestinal proteases on purified human 
intrinsic factor-vitamin B12 (IF-B12) complex. Indian J Biochem Biophys.  April 
2003;40:139-142. 
 
73. Gueant JL, Champigneulle B, Djalali M, Bigard MA, Gaucher P, Hassouni A, et al. 
In-vitro test of haptocorrin degradation for biological diagnosis of exocrine 
pancreatic dysfunction using duodenal juice collected during endoscopy. Lancet 
1986;2:709-12. 
 
74. Wilcox CM, Yadav D, Ye T, Gardner TB, Gelrud A, Sandhu BS, et al. Chronic 
pancreatitis pain pattern and severity are independent of abdominal imaging 
findings. Clin Gastroenterol Hepatol 2015;13:552-60; quiz e28-9. 
 
75. Beyer G, Mahajan UM, Budde C, Bulla TJ, Kohlmann T, Kuhlmann L, et al. 
Development and Validation of a Chronic Pancreatitis Prognosis Score in 2 
Independent Cohorts. Gastroenterology 2017;153:1544-1554.e2. 
 
76. Whitcomb DC. Better Biomarkers for Pancreatic Diseases. Pancreas 
2015;44:1171-3. 
 
77. Rasch S, Valantiene I, Mickevicius A, Beer S, Rosendahl J, Charnley RM, et al. 
Chronic pancreatitis: Do serum biomarkers provide an association with an 
inflammageing phenotype? Pancreatology 2016;16:708-14. 
 
78. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic 
usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the 
differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab 
Anal. 2010;24:256-61. 
 
79. Han JM, Levings MK. Immune regulation in obesity-associated adipose 
inflammation. J Immunol 2013;191:527-32. 
 
80. Stepanova M, Rodriguez E, Birerdinc A, Baranova A. Age-independent rise of 
inflammatory scores may contribute to accelerated aging in multi-morbidity. 
Oncotarget 2015;6:1414-21. 
 
81. Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, et al. Immune 
system, cell senescence, aging and longevity--inflamm-aging reappraised. Curr 
Pharm Des. 2013;19:1675-9. 
 
82. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a 
decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534-40. 
  
 
This article is protected by copyright. All rights reserved. 
 
30 
 
83. Hickson M. Malnutrition and ageing. Postgrad Med J. 2006;82:2-8. 
 
Table 1: Baseline characteristics of controls and chronic pancreatitis patients 
Characteristic  Controls (266) Chronic 
pancreatitis 
Patients  (301) 
P value 
Age at enrollment (Mean ±SD) 45.6 ± 13.4 50.76 ± 14.11 <0.001 
Male – n (%) 107 (40.2) 151 (50.1) <0.05 
Race – n (%) 
  Caucasian 
  African-American 
 
155 (58.3) 
111 (41.7) 
 
214 (71.1) 
87 (28.9) 
 
 
<0.01 
Body mass index (BMI) – n (%) 
  Underweight (<18 kg/m2) 
  Normal (18-25 kg/m2) 
  Overweight (≥ 25-30 kg/m2) 
  Obese (> 30 kg/m2) 
 
3 (1.1) 
64 (24.1) 
97 (36.5) 
102 (38.3) 
 
25 (8.3) 
141 (46.8) 
78 (25.9) 
56 (18.6) 
 
 
 
<0.001 
Drinking category*  
  Lifetime abstainer 
  Light drinker 
  Moderate drinker 
  Heavy/very heavy drinker 
  Missing data 
 
34 (26.4) 
32 (24.8) 
24 (18.6) 
39 (30.2) 
137  
 
42 (14.5) 
58 (20.0) 
36 (12.4) 
154 (53.1) 
11  
 
 
<0.001 
Alcohol consumption – n (%) 
  Never 
  Past 
  Current  
 
34 (12.8) 
56 (21.1) 
176 (66.2) 
 
42 (14.0) 
197 (65.5) 
62 (20.6) 
 
 
<0.001 
Cigarette smoking – n (%) 
  Never 
  Past 
  Current 
 
130 (48.9) 
74 (27.8) 
62 (23.3) 
 
67 (22.3) 
78 (25.9) 
156 (51.8) 
 
 
<0.001 
Vitamin Supplementation – n (%) 120 (45.1) 168 (55.8) <0.05 
  SD= standard deviation 
  Missing data: BMI (1 CP), drinking category (CP 12, controls 152), vitamin supplementation (CP 1, 
controls 1);  
  Percentages shown are based on effective numbers.  
  *Based on self-reported drinking during the maximum lifetime drinking period 
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Table 2: Etiology, diabetic status, duration of disease and pancreatic enzyme replacement 
therapy (PERT) usage and duration of disease in chronic pancreatitis patients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Characteristic  
N (%) 
Chronic Pancreatitis patients (301) 
Physician-defined alcohol etiology 
  No 
  Yes 
 
151 (50.2) 
150 (49.8) 
Diabetes mellitus diagnosis 
  No 
  Yes 
 
185 (61.5) 
116 (38.5) 
PERT usage 
  No 
  Yes 
 
135 (44.9) 
166 (55.1) 
Time since diagnosis 
  < 5 years 
  5-10 years 
  > 10 years 
  Missing data 
 
187 (62.1) (73.3) 
40 (13.3) (15.7) 
28 (9.3) (11.0) 
46 (15.3) (0.0) 
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Table 3: Serum vitamin, nutritional marker and biomarker levels (top) and deficiencies 
(bottom)  
in controls and chronic pancreatitis patients 
Serum vitamin, nutritional marker and biomarker levels 
Variable (reference 
range) 
Controls 
(266) 
Chronic 
pancreatiti
s 
Patients 
(301) p-value* 
Vitamin A (30-105 
µg/dL) 45.4 [37.1, 54.3] 
40.9 [30.3, 
51.9] 0.001 
Vitamin B12 
(cobalamin) (210-
911 pg/mL) 609.5 [466.5, 794.5] 
703.0 
[565.0, 
923.0] < 0.001 
Vitamin D (25-
hydroxy vitamin D3) 
(10-55 ng/mL) 
22.2 [12.3, 32.8] 
20.7 [11.5, 
32.8] 0.92 
Vitamin E (α-
tocopherol) (5.7-19.9 
mg/L) 
10.3 [8.4, 12.8] 
8.7 [6.5, 
12.2] < 0.001 
Vitamin E (γ -
tocopherol) ( ≤4.3 
mg/L) 
2.2 [1.6, 2.9] 
1.8 [1.1, 
2.8] < 0.001 
Osteocalcin (9-42 
ng/mL) 10.0 [7.3, 14.5] 
7.9 [5.0, 
12.4] < 0.001 
Prealbumin 
(transthyretin) (15-
36 mg/dL) 
27.0 [23.0, 30.0] 
23.0 [19.0, 
27.0] < 0.001 
Retinol Binding 
Protein (15-67 
μg/mL) 
37.0 [30.2, 44.1] 
34.5 [25.6, 
44.0] 0.055 
C-reactive protein 
(CRP) (<0.7 mg/dL) 0.2 [0.1, 0.5] 
0.3 [0.1, 
1.0] < 0.001 
TNF-α (pg/mL)**  
3.0 [2.0, 3.0] 
3.0 [2.0, 
4.0] 0.92 
Serum vitamin and nutritional marker deficiencies† 
Variable 
Controls 
(266) 
Chronic pancreatitis 
Patients (301) 
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Vitamin A (<30 μg/dL) N(%) 20 (7.5) 75 (24.9) 
Vitamin B12 (cobalamin) (<210 pg/mL) 2 (0.8) 1 (0.3) 
Vitamin D (25-hydroxy vitamin D3) (<10 ng/mL) 49 (18.4) 63 (20.9) 
Vitamin E (α-tocopherol) (<5.7 mg/L) 8 (3.0) 54 (17.9) 
Vitamin E (γ -tocopherol) (>4.3 mg/L) 20 (7.5) 14 (4.7) 
Osteocalcin (<9 ng/mL) 114 (42.9) 176 (58.5) 
Prealbumin (transthyretin) (<15 mg/dL) 6 (2.3) 46 (15.3) 
Retinol Binding Protein (<15 μg/mL) 4 (1.5) 14 (4.7) 
  *Adjusted for multiple comparisons using Hommel’s procedure 
** TNF-α does not have a standard reference range 
† Unadjusted levels; Deficiency thresholds based on Quest Diagnostics Inc. laboratory, Madison, 
New Jersey 
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Table 4: Multivariable linear regression analyses for predictors of serum levels of vitamins, nutritional markers and biomarkers 
  
Vitamin A Vitamin B12 Vitamin D3 Vitamin E α 
Tocopherol 
Vitamin E γ  
Tocopherol 
Osteocalcin Pre-albumin Retinol  
Binding  
Protein 
C reactive  
protein 
TNF α 
 
  
(Intercept) 3.666 ‡ 6.275 ‡ 3.112 ‡ 2.349 ‡ 1.357 ‡ 2.321 ‡ 3.201 ‡ 3.483 ‡ -2.356 ‡ 1.648 ‡ 
Diagnosis (CP) -0.105 * 0.237 ‡ -0.104 ^ -0.189 ‡ -0.083 * -0.319 ‡ -0.100 * -0.097 * 0.681 ‡ -0.034  
Race (African-American) -0.050  0.175 ‡ -0.508 ‡ -0.131 ‡   -0.124  0.074 ^ -0.102 † 0.133  -0.080  
Sex (male)           0.031  0.043      0.084  
Age (centered) 0.003 *     0.006 ‡   0.006 *   0.004 † 0.008 ^   
Vitamin  
Supplementation (yes) 
0.127 ‡ 0.148 ‡ 0.233 ‡ 0.133 ‡ -0.152 ‡     0.085 *   0.112  
Current BMI 
          
Underweight       -0.171 * 0.089    -0.064    -0.522 ^   
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Overweight       0.032  0.182 ‡   -0.001    0.466 †   
Obese       0.025  0.294 ‡   -0.104 †   1.035 ‡   
Alcohol consumption 
          
Former 0.093            0.031  0.117 *     
Current 0.138 *           0.101 * 0.151 †     
Smoking status 
          
Former     0.094  0.041  0.102 *   -0.061        
Current     -0.169 * -0.090 * 0.139 †   -0.064 ^       
Diagnosis: Race Interaction -0.180 * -0.201 †       0.266 * -0.129 *   0.528 * 0.319 * 
Sex: Age Interaction           -0.019 ‡         
 ^ p<0.10 * p<0.05 † p<0.01 ‡ p<0.001  
All serum levels underwent log transformation prior to modeling except for Vitamin E γ Tocopherol and TNF α, which were transformed using a square root function.  
 
